News for Eupraxia Pharmaceuticals Inc. (EPRX.TO)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

VICTORIA, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ('Eupraxia” or the 'Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company’s management team will present and participate at the following upcoming investor conferences:

Shares of Venus Concept Inc. VERO rose sharply in today's pre-market trading after Madryn Asset Management increased its stake in the company to 85.5%. Venus C...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

VICTORIA, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (”œEupraxia” or the ”œCompany”) (TSX: EPRX) ( EPRX), a clini

**media[643820]**

**media[627670,627671]**

**media[617953]**

Eupraxia Pharmaceuticals (EPRX) reports a Q1 2025 net loss of $6.8 million, compared to $6.2 million in Q1 2024. The company maintains a strong cash pos

Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE)

Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months af

VICTORIA, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (”œEupraxia” or the ”œCompany”) (EPRX) (TSX:EPRX), a clinic

PR NewswireVICTORIA, BC, March 20, 2025 VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPR

PR NewswireVICTORIA, BC, Feb. 25, 2025 Histological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increa

PR NewswireVICTORIA, BC, Feb. 18, 2025 - Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the roleVICTORIA, BC, Feb. 18, 2025 /PRNewswi

PR NewswireVICTORIA, BC, Nov. 20, 2024 DiffuSphereâ„¢ is designed to enable precise drug delivery at therapeutic dose levels directly into target tissues,

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Corcept Therapeutics (CORT), a pharmaceutical company specializing in hormone regulation therapies, experienced a significant stock movement with a 5.04% drop i